ijcr@oajrc.org

国际临床研究杂志

International Journal of Clinical Research

您当前位置:首页 > 精选文章

International Journal of Clinical Research. 2024; 8: (1) ; 10.12208/j.ijcr.20240035 .

Effect of different doses of octreotide in the treatment of patients with severe acute pancreatitis
不同剂量奥曲肽治疗重症急性胰腺炎患者效果

作者: 沈全英 *

开滦集团蔚州矿业有限公司医院 河北张家口

*通讯作者: 沈全英,单位:开滦集团蔚州矿业有限公司医院 河北张家口;

引用本文: 沈全英 不同剂量奥曲肽治疗重症急性胰腺炎患者效果[J]. 国际临床研究杂志, 2024; 8: (1) : 106-108.
Published: 2024/1/20 14:39:48

摘要

目的 观察重症急性胰腺炎病人采取不同剂量奥曲肽的疗效差异。方法 回顾性分析我院确诊医治共86例重症急性胰腺炎患者临床资料,时段2022年7月至2023年7月。依照奥曲肽用药剂量的差别分成两组,其中每天0.6mg奥曲肽归为常规剂量组(共43例),每天1.2mg奥曲肽归为大剂量组(共43例)。从治疗效果、症状消退时间、不良反应各方面对两组作出评价。结果 观察组相比对照组,其临床总有效率提高幅度更明显,两组统计学有显著意义(P<0.05)。观察组相比对照组,其发热、腹痛、腹胀消退时间减少幅度更明显,两组统计学有显著意义(P<0.05)。观察组相比对照组,其不良反应总发生率[1]统计学无显著意义(P>0.05)。结论 重症急性胰腺炎病人采取大剂量奥曲肽治疗相比常规剂量具有更显著疗效,可加快症状消退,不会增加不良反应。

关键词: 重症急性胰腺炎;不同剂量;奥曲肽

Abstract

Objective To observe the effects of different doses of octreotide in patients with severe acute pancreatitis.
Methods Clinical data of 86 patients with severe acute pancreatitis diagnosed and treated in our hospital from July 2022 to July 2023 were retrospectively analyzed. According to the difference of octreotide dosage, they were divided into two groups, of which 0.6mg octreotide per day was classified as the conventional dose group (43 cases), and 1.2mg octreotide per day was classified as the high-dose group (43 cases). The two groups were evaluated from the aspects of treatment effect, symptom resolution time and adverse reactions.
Results Compared with the control group, the total clinical effective rate of the observation group increased more significantly, and there was statistically significant significance between the two groups (P < 0.05). Compared with the control group, the regression time of fever, abdominal pain and abdominal distension decreased more significantly in the observation group, with statistically significant significance between the two groups (P < 0.05). Compared with the control group, the total incidence of adverse reactions in the observation group [1] was not statistically significant (P > 0.05).
Conclusion   The treatment of severe acute pancreatitis with high-dose octreotide is more effective than conventional dose, which can accelerate the resolution of symptoms without increasing adverse reactions.

Key words: Severe acute pancreatitis; Different doses; Octreotide

参考文献 References

[1] 陈锦裕. 乌司他丁联合奥曲肽治疗重症急性胰腺炎患者的临床效果及其作用机制研究[J]. 中外医学研究, 2023, 21(13):44-47. 

[2] 祁海芳,王艳玲,龚莹莹,等. 奥曲肽、乌司他丁联合泮托拉唑钠治疗重症急性胰腺炎的临床效果[J]. 中国当代医药,2019,26(21):79-82. 

[3] 谭云辉. 乌司他丁与奥曲肽对重症急性胰腺炎PAF、ICAM-1、免疫功能 水平影响及临床治疗效果分析[J]. 解放军预防医学杂志,2019,37(1):32-35.

[4] 邢宝鹏,李海峰,金小渊,等. 不同剂量醋酸奥曲肽对重症急性胰腺炎患者临床疗效的影响[J]. 中国中西医结合急救杂志,2017,24(6):622-624.

[5] 周殿耀,李林敏. 奥曲肽联合乌司他丁治疗重症胰腺炎患者的临床疗效及其安全性[J]. 临床合理用药杂志, 2022, 15 (15): 30-32,39. 

[6] 李广锋,刘冬梅. 不同剂量醋酸奥曲肽对重症急性胰腺炎患者临床疗效的影响[J]. 中国保健营养,2018,28(32): 126. 

[7] 周学敏. 奥曲肽联合乌司他丁对重症急性胰腺炎的疗效及对血清炎症因子水平的影响[J]. 中国现代医生, 2021, 59(36):88-91.

[8] 王萌,袁军侠,文明霞. 奥曲肽联合乌司他丁治疗老年急性胰腺炎患者的疗效及对血清Beclin-1和LC3水平的影响[J]. 临床和实验医学杂志,2022,21(19):2032-2036.